PTC Therapeutics (PTCT) Projected to Release Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is expected to be releasing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect PTC Therapeutics to post earnings of $0.2071 per share and revenue of $304.60 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.68. The business had revenue of $360.52 million during the quarter, compared to analyst estimates of $298.63 million. During the same period last year, the company earned ($0.83) earnings per share. The business’s revenue for the quarter was up 101.5% compared to the same quarter last year. On average, analysts expect PTC Therapeutics to post $1.19 EPS for the current fiscal year and $1.90 EPS for the next fiscal year.

PTC Therapeutics Price Performance

PTCT stock opened at $62.62 on Thursday. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87. The company’s 50 day moving average is $66.73 and its two-hundred day moving average is $71.65.

Analysts Set New Price Targets

PTCT has been the subject of several research analyst reports. Barclays upped their target price on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Royal Bank Of Canada cut their price target on shares of PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, October 7th. Raymond James Financial set a $106.00 price target on shares of PTC Therapeutics in a research report on Tuesday. Cantor Fitzgerald upped their price objective on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Finally, UBS Group restated a “buy” rating and issued a $90.00 price objective (up from $80.00) on shares of PTC Therapeutics in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $94.93.

Insider Buying and Selling

In related news, VP Mark Boulding sold 435 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the sale, the vice president directly owned 105,272 shares of the company’s stock, valued at $6,754,251.52. This trade represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the completion of the transaction, the director owned 22,500 shares in the company, valued at approximately $1,466,100. This trade represents a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,370 shares of company stock valued at $5,322,261 over the last three months. 5.30% of the stock is currently owned by company insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.